Möchten Sie immer auf dem neuesten Stand bleiben?

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both...

Addition Therapeutics announces multiple oral and poster presentations at the upcoming ASGCT Annual Meeting, May 11-15, 2026, in Boston.

New York, USA, April 27, 2026 (GLOBE NEWSWIRE) -- Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment...

Precision Fermentation Market: Global Trends, Key Players & Forecast (2026–2035) by Application, Ingredient, Microbe and Fermentation Type

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S. Food...

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in...

DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

Ottawa, April 24, 2026 (GLOBE NEWSWIRE) -- Rising global incidence of cancer and cardiovascular diseases is driving demand for advanced diagnostic imaging and targeted radiopharmaceutical therapies....

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Clinical Trial Management System Market Report 2026" has been added to ResearchAndMarkets.com's offering. The clinical trial management system...

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Electronic Trial Master File (eTMF) Systems Market Report 2026" has been added to ResearchAndMarkets.com's offering. The electronic trial master...